Improved safety of basiliximab (Simulect®) over antithymocyte globulin (Thymoglobulin®) induction therapy in heart transplantation
The Journal of Heart and Lung Transplantation(2005)
Abstract
Antibody induction therapy is currently used in a large proportion of patients despite tolerability issues. The aim of this prospective, randomized, multicentre study was to compare basiliximab vs antithymocyte globulin (ATG) to evaluate if basiliximab could supply a benefit on tolerability with no penalty on efficacy.
MoreTranslated text
Key words
antithymocyte globulin,heart transplantation,basiliximab,induction therapy
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined